Related Experiment Video
Updated: Apr 30, 2026

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism
Bin Guan1, Sunita K Agarwal2, James M Welch2
1Ophthalmic Genomics Laboratory, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
A patient with primary hyperparathyroidism (PHPT) and developmental anomalies was found to have a de novo ZFX gene variant. This finding suggests ZFX gene testing may benefit PHPT patients with congenital anomalies.
Area of Science:
- Endocrinology
- Genetics
- Oncology
Background:
- Primary hyperparathyroidism (PHPT) is a common endocrine disorder.
- PHPT management typically involves parathyroidectomy.
- Genetic factors can predispose individuals to PHPT.
Observation:
- A 51-year-old woman with a history of PHPT, osteoporosis, and learning disability presented with recurrent hypercalcemia.
- Physical examination revealed dysmorphic features, multiple nevi, and scoliosis.
- Laboratory tests confirmed hypercalcemia and elevated parathyroid hormone (PTH) levels.
Findings:
- The patient underwent successful parathyroidectomy, normalizing calcium and PTH levels.
- Genetic testing identified a de novo heterozygous missense variant (p.R764W) in the ZFX gene.
- ZFX gene variants are associated with X-linked intellectual disability, congenital anomalies, and PHPT.
Implications:
- This case highlights a potential genetic link between ZFX variants, PHPT, and developmental anomalies.
- ZFX gene testing may be beneficial for patients with PHPT and congenital anomalies, even without a family history.
- Further research is warranted to establish ZFX as a diagnostic marker for specific PHPT subtypes.
More Related Videos
08:22A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
Published on: September 16, 2019
06:21Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Point and Frameshift Mutations